China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the latest clinical data for its investigational drugs 9MW2821 and 8MW0511 at the upcoming 2023 European Society for Medical Oncology (ESMO) Congress. This presentation underscores the company’s commitment to advancing innovative therapies in oncology.
9MW2821: Promising Results in Solid Tumors
9MW2821 is an antibody-drug conjugate (ADC) specifically targeting Nectin-4. The Phase I/II study, which will be updated at the congress, has enrolled 195 patients. Notably, the objective response rate (ORR) and disease control rate (DCR) for 115 solid tumor subjects receiving a dose of 1.25 mg/kg or more are 43.5% and 81.7%, respectively. Among 37 evaluable subjects with urothelial carcinoma in the 1.25 mg/kg dose group, the ORR reached 62.2%, with a DCR of 91.9%. Overall, the safety profile of 9MW2821 appears favorable.
8MW0511: Efficacy in Neutropenia Management
8MW0511 is a recombinant human serum albumin-human granulocyte colony-stimulating factor fusion protein. The Phase III study results indicate that 8MW0511 demonstrates significant clinical efficacy, comparable to the positive control drug, while effectively reducing the incidence and duration of grade 4 neutropenia. Notably, the incidence of grade 4 neutropenia during the second to third cycles is significantly lower than that of the control drug. The overall safety profile is similar to that of the positive control, with good tolerability and a manageable safety profile for human medication.-Fineline Info & Tech
